Targeting Migration, Survival and Immune-response Pathways In cancer

The Biokine Story

Biokine Therapeutics is a private biopharmaceutical company founded in 2000. Biokine lead product BKT140/BL8040, is a high affinity, long-acting CXCR4 receptor inhibitor that already passed successful Phase III for Stem Cell Mobilization and Phase I/II for Immunotherapy for cancer together with immune check point inhibitor Pembrolizumab (Keytruda, Merck) and Atezolizumab (Tecentriq, Genentech/Roche). BL8040 was licensed to BiolineRx and is being developed in the clinic together with BiolineRx Ltd. (NASDAQ:BLRX). Biokine pipeline also include BKT300 which was Identified, Biokine’s Might™ phenotypic screen. BKT300 is a first in class small molecule that specifically controls migration and survival pathways in cancer cells via targeting the protein regulator of cytokinesis 1 (PRC1) , a novel less explored target.  BKT-300 is in IND enabling studies, 12 months to IND-submission. Phase I/II dose-finding study, will evaluate its safety and initial efficacy in patients with aggressive solid tumors that have high expression of Ki67 and CDC25c. BKT-300 has a strong worldwide IP coverage (life span till 2042) including composition and method of use patents. Biokine has also developed a suite of unique technologies, MigHit™ – which is a phenotypic screen that allows identification of small molecules targeting migration and survival pathways in cancer and ImmunHit™ which is platform technology enables identification of small molecules targeting IFN-g mediated immune response in cancer and inflammation.

Our Mission

temp-visionThe mission of Biokine is devoted to identifying novel molecular and cellular mechanisms that regulate tumor development and metastasis and to develop novel therapeutics against these devastating diseases.

Our Mission

According to estimates from the International Agency for Research on Cancer (IARC), there were 12.7 million new cancer cases in 2008 worldwide,of which 5.6 million occurred in economically developed countries and 7.1 million in economically developing countries. The corresponding estimates for total cancer deaths  in 2008 were 7.6 million (about 21,000 cancer deaths a day), 2.8 million in economically developed countries and 4.8 million in economically developing countries. By 2030, the global burden is expected to grow to 21.4 million new cancer cases and 13.2 million cancer deaths simply due to the growth and aging of the population, as well as reductions in childhood mortality and deaths from infectious diseases in developing countries.

In 2014, there will be an estimated 1,665,540 new cancer cases diagnosed and 585,720 cancer deaths in the US. Cancer remains the second most common cause of death in the US, accounting for nearly 1 of every 4 deaths. Global Cancer Facts & Figures   www.cancer.org

Recent News

Motixafortide in Second Line Metastatic Pancreatic Cancer (PDAC)

December 16th, 2020|Comments Off on Motixafortide in Second Line Metastatic Pancreatic Cancer (PDAC)

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical Company focused on oncology, today announced results from the triple combination arm of the Company's COMBAT/KEYNOTE-202 clinical study evaluating motixafortide (BL-8040) in combination with KEYTRUDA® [...]

BioLineRx Announces Positive Results from Interim Analysis of GENESIS Phase 3 Trial of Motixafortide (BL-8040) in Stem Cell Mobilization.

October 30th, 2020|Comments Off on BioLineRx Announces Positive Results from Interim Analysis of GENESIS Phase 3 Trial of Motixafortide (BL-8040) in Stem Cell Mobilization.

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, today announced positive results from a planned interim analysis of the ongoing GENESIS Phase 3 trial of motixafortide for stem cell mobilization (SCM) [...]

BioLineRx Announces Publication of Data from Ongoing COMBAT/KEYNOTE-202 Clinical Trial in Nature Medicine.

May 27th, 2020|Comments Off on BioLineRx Announces Publication of Data from Ongoing COMBAT/KEYNOTE-202 Clinical Trial in Nature Medicine.

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical Company focused on oncology, today announced that a paper, entitled 'BL-8040, a CXCR4 Antagonist, in Combination with Pembrolizumab and Chemotherapy for Pancreatic Cancer: The COMBAT Trial,' has [...]

BioLineRx Announces Notice of Allowance from USPTO for Patent Covering Motixafortide (BL-8040) in Combination With Anti-PD-1 for the Treatment of Any Type of Cancer

February 27th, 2020|Comments Off on BioLineRx Announces Notice of Allowance from USPTO for Patent Covering Motixafortide (BL-8040) in Combination With Anti-PD-1 for the Treatment of Any Type of Cancer

BioLineRx Ltd. (NASDAQ: BLRX), (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today that a Notice of Allowance has been issued by the United States Patent and Trademark Office (USPTO) for a patent [...]

Bio BioLineRx Receives Orphan Drug Designation for Motixafortide (BL-8040) for the Treatment of Pancreatic Cancer in Europe.

January 14th, 2020|Comments Off on Bio BioLineRx Receives Orphan Drug Designation for Motixafortide (BL-8040) for the Treatment of Pancreatic Cancer in Europe.

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, today announced that the European Commission (EC) has granted Orphan Drug Designation to its lead oncology candidate, Motixafortide (BL-8040), for the treatment of pancreatic cancer, [...]

Updated Phase 2a Data From Triple Combination Arm of COMBAT/KEYNOTE

December 13th, 2019|Comments Off on Updated Phase 2a Data From Triple Combination Arm of COMBAT/KEYNOTE

BioLineRx Announces Updated Phase 2a Data From Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Patients With Second-line Metastatic Pancreatic Cancer. Combination of BL-8040, KEYTRUDA® and chemotherapy demonstrates a 32% overall response rate and a 77% [...]